+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Incyte Corp (INCY) - Financial and Strategic SWOT Analysis Review

Incyte Corp (INCY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Incyte Corp (Incyte) is a biopharmaceutical company, which discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi. The company’s pipeline portfolio encompasses drugs for the treatment of lung cancer, graft versus host disease, b-cell malignancies, solid tumors, non-small cell lung cancer, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.

Incyte Corp Key Recent Developments

  • Mar 14, 2023: Incyte announces data from across its oncology portfolio will be presented at the AACR Annual Meeting 2023
  • Mar 08, 2023: Caris signs research partnership with Incyte for oncology pipeline
  • Jan 17, 2023: Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
  • Dec 10, 2022: Incyte announces data from two LIMBER studies evaluating combination treatments in patients with Myelofibrosis (MF) Presented at ASH 2022

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Incyte Corp - Key Facts
  • Incyte Corp - Key Employees
  • Incyte Corp - Key Employee Biographies
  • Incyte Corp - Major Products and Services
  • Incyte Corp - History
  • Incyte Corp - Company Statement
  • Incyte Corp - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Incyte Corp - Business Description
  • Product Category: Iclusig
  • Performance
  • Product Category: Jakafi
  • Performance
  • Product Category: Jakavi Product Royalty Revenue
  • Performance
  • Product Category: Milestone and Contract Revenue
  • Performance
  • Product Category: Minjuvi
  • Performance
  • Product Category: Olumiant Product Royalty Revenue
  • Performance
  • Product Category: Opzelura
  • Performance
  • Product Category: Pemazyre
  • Performance
  • Product Category: PEMAZYRE product royalty revenues
  • Capital Expenditure
  • Other Break-up: Tabrecta Product Royalty revenue
  • Performance
  • R&D Overview
  • Incyte Corp - Corporate Strategy
  • Incyte Corp - SWOT Analysis
  • SWOT Analysis - Overview
  • Incyte Corp - Strengths
  • Incyte Corp - Weaknesses
  • Incyte Corp - Opportunities
  • Incyte Corp - Threats
  • Incyte Corp - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Incyte Corp, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Incyte Corp, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Mar 14, 2023: Incyte announces data from across its oncology portfolio will be presented at the AACR Annual Meeting 2023
  • Mar 08, 2023: Caris signs research partnership with Incyte for oncology pipeline
  • Jan 17, 2023: Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
  • Dec 10, 2022: Incyte announces data from two LIMBER studies evaluating combination treatments in patients with Myelofibrosis (MF) Presented at ASH 2022
  • Dec 05, 2022: Incyte signs partnership agreement with CMS for ruxolitinib cream
  • Nov 08, 2022: Incyte and Mirati enter trial partnership for solid tumour therapy
  • Nov 07, 2022: Data from Incyte’s oncology portfolio to be presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
  • Nov 03, 2022: More than 50 Abstracts from Incyte’s Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting
  • Nov 01, 2022: Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
  • Oct 25, 2022: GENESIS Pharma announces the extension of its commercial agreement with Incyte
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Incyte Corp, Key Facts
  • Incyte Corp, Key Employees
  • Incyte Corp, Key Employee Biographies
  • Incyte Corp, Major Products and Services
  • Incyte Corp, History
  • Incyte Corp, Subsidiaries
  • Incyte Corp, Key Competitors
  • Incyte Corp, Ratios based on current share price
  • Incyte Corp, Annual Ratios
  • Incyte Corp, Interim Ratios
  • Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Incyte Corp, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Incyte Corp, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Incyte Corp, Performance Chart (2018 - 2022)
  • Incyte Corp, Ratio Charts
  • Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Incyte Corp, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Shepherd Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc
  • Biogen Inc
  • Oxford Biomedical Research Inc
  • Celgene Corp
  • Amgen Inc
  • Merck & Co Inc
  • Oxford Biomedical Research Inc
  • Regeneron Pharmaceuticals Inc
  • Gilead Sciences Inc
  • Nippon Shinyaku Co Ltd
  • Celgene Corp
  • Constellation Pharmaceuticals Inc
  • Biogen Inc
  • CTI BioPharma Corp
  • Immunitas Therapeutics Inc
  • Shepherd Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Constellation Pharmaceuticals Inc
  • Nippon Shinyaku Co Ltd
  • Gilead Sciences Inc
  • Regeneron Pharmaceuticals Inc
  • Merck & Co Inc
  • Immunitas Therapeutics Inc
  • CTI BioPharma Corp